Overall survival based on sequencing of fruquintinib, regorafenib, and TAS-102 with or without bevacizumab in treatment-refractory metastatic colorectal cancer.
Jennah Bauernfeind(Mayo Clinic Hospital), Daniel H. Ahn(Mayo Clinic Hospital), Mohamad Bassam Sonbol(WinnMed), Fang‐Shu Ou(Mayo Clinic), Tanios Bekaii‐Saab(WinnMed), Oluseyi Abidoye(Mayo Clinic), Anina Peersen(Mayo Clinic), Christina Wu(Mayo Clinic Hospital)
Cited by 0
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
|British Journal of Cancer|2019|409